Rolapitant , NDA IN 2014

New Drug Approvals

ROLAPITANT HYDROCHLORIDE

• Rolapitant HCl
• Rolapitant hydrochloride
• Sch 619734
• SCH619734
• UNII-57O5S1QSAQ

(5S ,8S)-8-[[(1R)-1-[3 ,5-
Bis(trifluoromethyl)phenyl] ethoxy] methyl]-8-phenyl-1,7-
diazaspiro[4.5]decan-2-one hydrochloride monohydrate.   

CAS 914462-92-3

Empirical Formula: C25H26F6N2O2 · HCl · H2O 

Molecular Weight:  555 

USAN Name: Rolapitant hydrochloride 

INN Name:  rolapitantum or rolapitant 

phase 3

CAS Number: 552292-08-7 (rolapitant free base); 914462-92-3 (rolapitant HCl monohydrdate).

It is in late-stage trials of its drug rolapitant, which showed promising mid-stage results in reducing nausea and vomiting in patients undergoing chemotherapy

Rolapitant hydrochloride is a tachykinin neurokinin 1 (NK1) antagonist in phase III clinical trials at Tesaro for the prevention of chemotherapy-induced nausea and vomiting (CINV). Phase II clinical trials are also under way at OPKO for this indication. At Merck & Co., phase II clinical studies were also under way for the treatment of chronic idiopathic cough and for the prevention of chemotherapy-induced nausea; however, no recent developments have been…

View original post 3,206 more words